The amount of research done is highly depended on donor funds. While researchers would prefer to investigate the drug’s impact on all the types of people who use it, for example men, women, children and teens, senior citizens, pregnant women, people with a disability, people with mental health issues, they know that donors have a preference for funding certain groups, for whom they feel more empathy, for example children and pregnant women. It is hard to get funding for groups who donors struggle to emotionally connect with.
When these concerned parties present their findings on the negative effects of the drug, they are challenged to provide evidence-upon-evidence-upon-evidence to back up their concerns, yet the pharmaceutical company isn’t held to the same standards to provide evidence that the drug is safe.
Imagine further that the system that monitors the trade and distribution of this drug (and all drugs), and is supposed to keep illegal and counterfeit drugs out of the legal market, is an old paper-based system, which doesn’t integrate with customs services and has been shown to have significant loopholes.